Section 9.3: Prescription Labeling Requirements in Texas

Section 9.3: Prescription Labeling Requirements in Texas

Prescription labeling is a critical component of patient safety, ensuring that patients receive clear, legible, and accurate instructions on how to take their medications. In Texas, the labeling of dispensed prescriptions is heavily regulated by the Texas State Board of Pharmacy (TSBP) under Rule 22 TAC §291.33(c)(7). Pharmacists must be familiar with every mandatory label element, specific formats for generic drug labeling, beyond-use date requirements, and exceptions for specialized dispensing.

Equally important—and heavily tested under NABP Competency 3.7—is recognizing when the drug product itself may not be dispensed at all. Accurate labeling cannot cure an adulterated, misbranded, expired, recalled, damaged, illegitimate, or incorrectly selected product. The final check before release must confirm both that the label is correct and that the physical product is legal and safe to dispense.

Mandatory Prescription Label Elements

Every prescription container dispensed to an outpatient in Texas must bear a label firmly affixed to the container. The label must contain the following information in a clear and legible format:

1. Pharmacy Information: The name, address, and telephone number of the pharmacy dispensing the prescription.
2. Prescription Number: A unique serial number (Rx number) identifying the prescription.
3. Date of Dispensing: The date the prescription was verified and dispensed by the pharmacist.
4. Patient Name: The name of the patient. If the prescription is for an animal, the label must state the owner’s name and the animal's species (e.g., "Spot Smith (Canine)").
5. Prescriber Name: The name of the practitioner who issued the prescription.
6. Directions for Use: Clear and unambiguous instructions for administration as written by the prescriber.
7. Dispensing Pharmacist Initials: The written or electronic initials or identification code of the dispensing pharmacist. This is a key Texas-specific requirement used for auditing and tracing responsibility.
8. Drug Name and Strength: The name and strength of the drug dispensed.
9. Quantity Dispensed: The total number of dosage units or volume of medication dispensed.
10. Beyond-Use Date (BUD): The date after which the drug should not be used, which must be the shorter of:
    • One year from the date of dispensing.
    • The manufacturer's expiration date on the original stock bottle.
11. Ancillary Instructions: Any necessary accessory or cautionary labels (e.g., "Take with food" or "May cause drowsiness").

Generic Substitution Labeling Rules

When a pharmacist substitutes a generically equivalent drug or interchangeable biological product, Texas law requires specific labeling format to ensure the patient and healthcare providers know exactly what was dispensed.

The label must include:

• The generic name of the drug.
• The strength of the drug.
• The name of the manufacturer or distributor of the generic drug dispensed.
• The brand name of the prescribed drug, or a statement indicating that the generic drug is substituted for the brand-name drug (e.g., "Atorvastatin 20mg (generic for Lipitor) MFG: Sandoz").

This requirement prevents confusion, particularly if the patient is used to seeing a brand-name drug but receives a generic tablet that looks different. It also ensures that in the event of a drug recall, the manufacturer of the generic product can be immediately identified from the patient's bottle.

Beyond-Use Date (BUD) Guidelines

Pharmacists must distinguish between the manufacturer’s expiration date and the beyond-use date (BUD) applied to the prescription label.

• Manufacturer Expiration Date: The date determined by the manufacturer's stability testing, showing how long the drug remains stable in its original, unopened container.
• Dispensed Prescription BUD: Once a drug is transferred from the manufacturer's stock bottle to a standard prescription vial, it is exposed to environmental factors like light, air, and moisture. Under Texas law, the BUD placed on the prescription label is capped at one year from the date of dispensing, or the manufacturer's expiration date, whichever is sooner.
• Repackaged Unit-Dose Products: If a pharmacy repackages a drug into unit-dose packaging (e.g., blister cards for nursing homes), the BUD is 12 months from the repackaging date or the manufacturer's expiration date, whichever is shorter.

Drug Product Conditions That Prohibit Dispensing

A correctly printed label does not authorize release of an unfit product. Under the federal Food, Drug, and Cosmetic Act (FDCA), the Drug Supply Chain Security Act (DSCSA), and the Texas Pharmacy Act / TSBP rules, pharmacists must refuse to dispense when the product itself is legally or clinically unfit. Competency 3.7 tests the ability to identify these stop conditions and act—quarantine, notify, document—rather than "fix it in software" and send the patient home with a dangerous or illegal drug.

1. Adulterated Drug Products

Under the FDCA, a drug is adulterated when its purity, strength, quality, or integrity is compromised—even if the label is accurate. Classic adulteration scenarios in community practice include:

• Contamination with filth, microorganisms, or foreign matter.
• Strength that differs from what the label claims (e.g., degraded active ingredient).
• Storage outside labeled temperature, humidity, or light requirements that can destroy potency (e.g., insulin left on a hot delivery truck, refrigerated vaccine held at room temperature beyond allowed excursion time).
• Compounded preparations prepared under insanitary conditions or with ingredients that fail quality standards.

Texas application: Dispensing an adulterated drug violates both federal law and Texas Occupations Code / TSBP standards of practice. If stock is found contaminated, heat-damaged, or otherwise adulterated, the pharmacist must quarantine the product, remove it from active inventory, and document disposition. Do not dispense "the rest of the bottle" after discovering contamination in part of a lot.

2. Misbranded Drug Products

A drug is misbranded when its labeling is false, misleading, or incomplete under FDCA standards. Misbranding is distinct from adulteration: the chemical product may be fine, but the information accompanying it is unlawful. Examples that prohibit dispensing include:

• Stock bottles missing required manufacturer labeling, lot number, or expiration date.
• Labels that identify the wrong drug name, strength, or manufacturer relative to the contents.
• Prescription labels that omit mandatory Texas elements (pharmacy identity, Rx number, patient name, directions, dispensing pharmacist identification, BUD) when those omissions make the dispensed package noncompliant.
• Products whose outer carton and inner container disagree on identity or strength.

Exam distinction: Adulteration = problem with the article (composition/condition). Misbranding = problem with the label/representation. Either condition independently bars lawful dispensing until corrected through a legal pathway (e.g., returning to supplier, destroying stock, or—only when permitted—relabeling under manufacturer/repackager authority, never by casually rewriting a stock bottle in the pharmacy).

3. Expired Stock and Beyond-Use Limitations

Pharmacists may not dispense a drug after the manufacturer's expiration date on the stock container, and may not assign a patient-container BUD that exceeds the shorter of one year from dispensing or the manufacturer's expiration date.

• Expired manufacturer stock: If the stock bottle is past its expiration date, the product must be removed from active inventory. Partial use of an expired bottle is not allowed merely because "most tablets look fine."
• BUD shorter than patient expectation: Even if stock is in-date, the outpatient BUD cannot exceed one year from dispensing. If the manufacturer's date is sooner (e.g., expires in three months), the label BUD must reflect that earlier date.
• Reconstituted and compounded products: Use the BUD required by the manufacturer labeling or compounding standards (often days to weeks), not the default one-year outpatient rule.

Dispensing expired medication is a classic TSBP inspection finding and an MPJE stop-condition item.

4. Recalled Drugs

When FDA, the manufacturer, or a distributor issues a recall, pharmacies must identify affected lot numbers and stop dispensing immediately.

Texas practice points: Check lot numbers on the stock bottle against the recall notice before verifying. Generic substitution labeling that lists manufacturer/distributor helps identify which patients received a recalled lot. Do not dispense an alternate bottle from the same recalled lot "because the patient is waiting." Obtain unaffected stock or contact the prescriber for a therapeutic alternative.

5. Damaged, Compromised, or Unsealed Packaging

Physical package integrity is a dispensing prerequisite:

• Broken tablets, leaking liquids, cracked vials, or torn unit-dose blisters expose the drug to contamination and potency loss.
• Compromised seals on manufacturer stock (broken induction seals, evidence of prior opening by unknown persons) raise adulteration and diversion concerns.
• Water-damaged, crushed, or unlabeled secondary packaging that obscures identity or lot/expiration data prevents safe verification.

Damaged goods must be quarantined and not counted into a patient vial. For unit-of-use products (inhalers, insulin pens, ophthalmic droppers), damage to the device or tip can make the entire unit unsaleable even if some doses remain.

6. DSCSA: Suspect or Illegitimate Product

The federal Drug Supply Chain Security Act (DSCSA) requires pharmacies to accept only product with required transaction information/history/statement (or electronic tracing equivalents as the system matured) from authorized trading partners. Pharmacists must be able to identify suspect product (reason to believe it may be counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit) and illegitimate product (credible evidence that it is counterfeit, diverted, stolen, intentionally adulterated, or the subject of a fraudulent transaction).

When suspicion arises (wrong package appearance, altered lot stickers, missing DSCSA data, purchase outside the authorized chain):

1. Quarantine the product—do not dispense, return to stock for sale, or destroy before investigation if preservation is needed for tracing.
2. Investigate promptly with the supplier/manufacturer using DSCSA verification tools and trading-partner contact.
3. Notify FDA and trading partners as required if the product is determined illegitimate (including the illegitimate product reporting pathway).
4. Document quarantine, investigation steps, notifications, and final disposition.

Texas pharmacies remain subject to TSBP inspection for supply-chain and recordkeeping failures. "I bought it cheap from an unknown secondary source" is not a defense—unauthorized product is a hard stop under DSCSA and Texas wholesale/distribution rules.

7. Incorrect Product Selected (Wrong Drug / Wrong Strength / Wrong Form)

Selecting the wrong NDC, strength, dosage form, or release mechanism is both a medication error and a misbranding/wrong-drug event. Conditions that prohibit dispensing until corrected include:

• Wrong drug (e.g., hydroxyzine selected for hydralazine).
• Wrong strength or concentration.
• Wrong dosage form (tablet vs. capsule; IR vs. ER/XR).
• Wrong manufacturer product when the prescription or payer requires a specific NDC and the selected product is not therapeutically/legally interchangeable under Texas substitution rules.
• Look-alike/sound-alike pulls discovered during final verification.

The pharmacist's final check must compare the stock bottle NDC/label to the prescription and the patient label. If mismatch is found after counting, the entire prepared prescription is rejected; tablets are not "relabeled" onto a different drug's vial.

Decision Framework: Label Ready vs. Product Fit

Professional judgment note: Texas Occupations Code § 551.006 affirms the pharmacist's exclusive authority to refuse to dispense. Product-condition failures are among the clearest lawful grounds for refusal. Document the reason (expired lot, Class I recall, DSCSA quarantine, etc.), secure the product, and arrange a safe alternative pathway for the patient when clinically appropriate.

Specialized Labeling Scenarios

Texas law provides specific labeling exceptions and rules for unique clinical and institutional environments.

1. Small Immediate Containers

If a container is too small to accommodate a full prescription label (e.g., ophthalmic drops, inhaler canisters, small topical tubes), TSBP rules allow for alternative labeling:

• Immediate Container Label: Must contain at least the prescription number, patient name, drug name and strength, and the pharmacy name.
• Outer Packaging Label: The complete, fully compliant prescription label must be affixed to the outer package (e.g., the cardboard box containing the eye drops or inhaler).

2. Epinephrine Auto-Injectors and Standing Orders

Texas law allows prescribers to issue standing orders for epinephrine auto-injectors, asthma inhalers, or opioid antagonists to specific entities (such as school districts, daycare centers, or law enforcement agencies) rather than individual patients.

• Entity Labeling: When dispensing these prescriptions, the label must state the name of the entity (e.g., "Austin ISD - Crockett High School") instead of an individual patient's name.

3. Class C (Hospital) Inpatient Labeling

Medications dispensed for administration to inpatients within a hospital are not subject to outpatient labeling requirements. Instead, unit-dose or multi-dose containers must bear labels containing:

• Drug name and strength.
• Lot number and expiration date.
• Manufacturer's name.
• Directions for administration (if applicable). If a patient is discharged and sent home with medications, those discharge medications must be labeled according to the full outpatient (Class A) rules.

Common Exam Traps and Legal Nuances

• "Federal Transfer Warning": For controlled substances in Schedules II, III, and IV, the label must contain the warning: "Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed." Note that under federal law, this is not required for Schedule V or non-controlled legend drugs, although some pharmacies print it on all labels as a default.
• Dispensing Pharmacist Identification: TSBP inspectors routinely check prescription labels for the written or electronic initials/identification code of the dispensing pharmacist. The absence of this identifier on dispensed labels is a common source of administrative penalties.
• Animal Patient Requirements: A common MPJE question involves labeling a pet's prescription. Remember that listing only the owner's name is insufficient. The label must explicitly state the owner's name and the species of the animal.
• Expired vs. "Almost Expired": Dispensing stock that expires tomorrow is lawful if still in-date at dispensing and the patient BUD does not exceed the manufacturer date; dispensing stock that expired yesterday is prohibited regardless of how short the patient's course of therapy is.
• Recall After Partial Count: If a Class I recall posts while a prescription is mid-verification, stop and quarantine—do not finish counting the recalled lot into the vial.
• DSCSA vs. Ordinary Shortage Workaround: Buying prescription stock from an unauthorized seller to "help the patient" during a shortage creates suspect/illegitimate product risk and can prohibit dispensing of that inventory entirely.